Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy

• Autor(a) principal: Camargo,Carlos Henrique F.
• Data de Publicação: 2009
• Outros Autores: Teive,Hélio A.G., Zonta,Marise, Silva,Gilmar C., Oliveira,Marcelo R., Roriz,Maurício M., Brandi,Ivar V., Becker,Nilson, Scola,Rosana Hermínia, Werneck,Lineu César
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos de neuro-psiquiatria (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000100016
• topic: cerebral palsy; botulinum toxin; spasticity

We evaluated the safety and effectiveness of botulinum toxin A (BoNT/A) in the treatment of spasticity in 20 children with spastic diplegic cerebral palsy (CP). All the patients received injections in the gastrocnemius and soleus, and 15 received injections in the adductors. The total dose varied from 70 to 140 U (99.75±16.26 U), or 7.45±2.06 U/kg per patient. The treatment improved the patients' walking and gait pattern significantly. There was also a significant alteration in the heel-ground distance and increased motion of the ankle joint. These structural changes in the feet were sustained until the end of the follow-up, although the same was not observed for the functional parameters. Three patients complained of weakness in the lower limbs. In conclusion, BoNT/A is safe and effective when used in a single session of injections and produces a sustained structural modification of the lower limbs. However, functional changes are temporary and are only observed during the peak effect of the drug.